SCTB41

SCTB41 is an investigational agent whose form is not stated in the registry developed by Sinocelltech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SCTB41 of different doses,IV,every 3 weeks. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07662395 (SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT06600022, plans to enrol 441 participants with primary completion expected 2027-04-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.